Select the right BTK inhibitors and right dose regimen/frequency to treat CLL/non-Hodgkin

Identify a patient’s unique BTK mutation status See Data

Identify a patient’s unique BTK mutation status See Data
On-target engagement with the right drug to determine the %BTK occupancy of a drug and its active metabolites in blood cells See Data

On-target engagement with the right drug to determine the %BTK occupancy of a drug and its active metabolites in blood cells See Data
Select treatment by determining appropriate dosing level & frequency to achieve a clinical response See Data

Select treatment by determining appropriate dosing level & frequency to achieve a clinical response See Data
Monitor drug off-target effects to define dosing regimens & reduce safety risks See Data

Monitor drug off-target effects to define dosing regimens & reduce safety risks See Data

Improve and balance clinical response and drug safety for leukemia and non-Hodgkin’s lymphoma patients

Nextcea uses advanced LC-MS/MS platforms to identify and quantitate patients’ BTK mutation status, BTK inhibitor %occupancy and off-target effects.

Our clinical blood assays allow physicians and pharmaceutical sponsors to:

Select the “right” treatment for cancer patients based on their BTK mutation status (covalent vs. non-covalent drugs or combination of both).

Select the “right” treatment for cancer patients based on their BTK mutation status (covalent vs. non-covalent drugs or combination of both).
Evaluate dosing requirements for patients based the %occupancy of BTK inhibitors and active metabolites

Evaluate dosing requirements for patients based the %occupancy of BTK inhibitors and active metabolites
Reduce safety risks associated with the off-target effects of BTK inhibitors (ex. bleeding associated with ibrutinib).

Reduce safety risks associated with the off-target effects of BTK inhibitors (ex. bleeding associated with ibrutinib).

Identify and profile the percentage of functional BTK C481 mutations in patients over time

Identify and profile the percentage of functional BTK C481 mutations in patients over time
Absolutely quantitate the target %occupancy of BTK inhibitors (ex. ibrutinib, acalabrutinib, zanubrutinib) in patients’ white blood cells.

Absolutely quantitate the target %occupancy of BTK inhibitors (ex. ibrutinib, acalabrutinib, zanubrutinib) in patients’ white blood cells.
Correlate the %occupancy associated with clinical response (ex. the change in white blood cell count) in individual patients

Correlate the %occupancy associated with clinical response (ex. the change in white blood cell count) in individual patients